EP3789016A1 — Pharmaceutical compositions comprising meloxicam and rizatriptan
Assigned to Axsome Therapeutics Inc · Expires 2021-03-10 · 5y expired
What this patent protects
A solid dosage form medicament for use in the treatment by oral administration of a human migraine patient in need thereof, wherein the solid dosage form comprises a combination of (a) an inclusion complex of a meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD) (b) 400 mg t…
USPTO Abstract
A solid dosage form medicament for use in the treatment by oral administration of a human migraine patient in need thereof, wherein the solid dosage form comprises a combination of (a) an inclusion complex of a meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD) (b) 400 mg to 1000 mg of a bicarbonate, and (c) a rizatriptan; wherein the solid dosage form is an oral dosage form having a mean T<sub>max</sub> of meloxicam of less than 2 hours when orally administered in healthy human subjects.
Drugs covered by this patent
- Mobic (MELOXICAM) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.